BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 19136943)

  • 1. Transcriptome sequencing to detect gene fusions in cancer.
    Maher CA; Kumar-Sinha C; Cao X; Kalyana-Sundaram S; Han B; Jing X; Sam L; Barrette T; Palanisamy N; Chinnaiyan AM
    Nature; 2009 Mar; 458(7234):97-101. PubMed ID: 19136943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric transcript discovery by paired-end transcriptome sequencing.
    Maher CA; Palanisamy N; Brenner JC; Cao X; Kalyana-Sundaram S; Luo S; Khrebtukova I; Barrette TR; Grasso C; Yu J; Lonigro RJ; Schroth G; Kumar-Sinha C; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12353-8. PubMed ID: 19592507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
    Kim B; Lee H; Shin S; Lee ST; Choi JR
    J Mol Diagn; 2019 Jan; 21(1):163-170. PubMed ID: 30347268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.
    Giacomini CP; Sun S; Varma S; Shain AH; Giacomini MM; Balagtas J; Sweeney RT; Lai E; Del Vecchio CA; Forster AD; Clarke N; Montgomery KD; Zhu S; Wong AJ; van de Rijn M; West RB; Pollack JR
    PLoS Genet; 2013 Apr; 9(4):e1003464. PubMed ID: 23637631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia.
    Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Kearney HM; Greipp PT; Hoppman NL; Baughn LB; Ketterling RP
    Hum Pathol; 2019 Jul; 89():109-114. PubMed ID: 30267776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
    Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.
    Linhartova J; Hovorkova L; Soverini S; Benesova A; Jaruskova M; Klamova H; Zuna J; Machova Polakova K
    Mol Cancer; 2015 Apr; 14():89. PubMed ID: 25928096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 11. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course.
    Byrne JL; Carter GI; Davies JM; Haynes AP; Russell NH; Cross NC
    Br J Haematol; 1998 Dec; 103(3):791-4. PubMed ID: 9858233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel transcription-induced fusion RNAs in prostate cancer.
    Zhao S; Løvf M; Carm KT; Bakken AC; Hoff AM; Skotheim RI
    Oncotarget; 2017 Jul; 8(30):49133-49143. PubMed ID: 28467780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
    Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
    Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery.
    Piazza R; Pirola A; Spinelli R; Valletta S; Redaelli S; Magistroni V; Gambacorti-Passerini C
    Nucleic Acids Res; 2012 Sep; 40(16):e123. PubMed ID: 22570408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.